EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Controlled treatment trials in the irritable bowel syndrome: a critique



Controlled treatment trials in the irritable bowel syndrome: a critique



Gastroenterology 95(1): 232-241



The irritable bowel syndrome (IBS) is a common and poorly understood chronic condition that is treated with a great variety of drugs and other methods without notable enduring success. As there are no objective markers of improvement, and because there may be a very large placebo response, potential treatments for IBS are difficult to assess. Probably the only method that can reliably evaluate IBS treatments is the randomized, double-blind, placebo-controlled treatment trial.

(PDF emailed within 0-6 h: $19.90)

Accession: 001554992

Download citation: RISBibTeXText

PMID: 3286362

DOI: 10.1016/0016-5085(88)90319-8



Related references

Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. American Journal of Gastroenterology 91(2): 277-283, 1996

What is the relevance of a systematic review of pharmacological management in irritable bowel syndrome to older people? Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials. Journal of the American Geriatrics Society 49(9): 1249-1252, September, 2001

Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 48(2): 272-282, 2001

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Annals of Internal Medicine 133(2): 136-147, 2000

Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome A meta-analysis of randomized controlled trials. Gastroenterology 122(4 Suppl 1): A-465, April, 2002

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clinical Therapeutics 30(5): 884-901, 2008

Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clinic Proceedings 91(4): 456-468, 2016

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Alimentary Pharmacology & Therapeutics 39(10): 1161-1168, 2014

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clinical Gastroenterology and Hepatology 2(8): 675-682, 2004

The Irritable Bowel Syndrome Outcome Study IBSOS Rationale and design of a randomized, placebo-controlled trial with 12month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome. 2012

The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome. Contemporary Clinical Trials 33(6): 1293-1310, 2013

Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. American Health & Drug Benefits 7(5): 289-297, 2014

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine 95(4): E2534-E2534, 2016

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterology and Motility 15(1): 79-86, 2003